The Effect of Vinegar on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes

Not Applicable

Completed

• Conditions: Type 2 Diabetes
• Interventions: Dietary Supplement: Vinegar; Other: Placebo

• Registration Number: NCT02309424
• Lead Sponsor: Attikon Hospital

Brief Summary

This open, randomized, cross-over, placebo-controlled study aims to investigate the effects of vinegar on glucose metabolism, endothelial function and circulating lipid levels in subjects with impaired glucose tolerance or type 2 diabetes, using the arteriovenous difference technique.

Detailed Description

Subjects with IGT or type 2 diabetes will be randomised to consume 20ml vinegar (6% acetic acid) or placebo before a mixed meal. Plasma samples will be taken for 300min from the radial artery and from a forearm vein for measurements of glucose, insulin, triglycerides, non-esterified fatty acids (NEFA) and glycerol. Muscle blood flow will be measured with strain-gauge plethysmography. Glucose flux will be calculated as the arteriovenous difference of glucose multiplied by the blood flow rates.

Study Timeline

• Study Start: 2008-07
• Primary Completion: 2013-12
• Status Verified: 2014-12
• Study Completion: 2014-12
• Study First Submitted: 2014-12-01
• Study First Submitted QC: 2014-12-04
• Last Update Submitted: 2014-12-04
• Study First Posted: 2014-12-05
• Last Update Posted: 2014-12-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Subjects with impaired glucose tolerance or newly diagnosed type 2 diabetes before the initiation of medication therapy
2. Recreationally active
3. With stable body weight and diet during the last two months.

Exclusion Criteria

1. Any systemic disease (besides glucose abnormalities)
2. Any medication therapy
3. Diabetic complications

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Vinegar	Vinegar	0,50mmol vinegar (6% acetic acid)
Placebo	Placebo	50 ml water

Primary Outcome Measures

Name	Time	Method
Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal

Secondary Outcome Measures

Name	Time	Method
Plasma insulin levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma triglyceride levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma NEFA levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma glycerol levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Number of participants with adverse events	300 min postmeal
Plasma glucose levels following meal ingestion (area under the plasma concentration versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Muscle blood flow following meal ingestion (area under the blood flow rates versus time curve-AUC)	0, 30, 60, 90, 120, 180, 240, 300 min postmeal